Unveiling the BRAF fusion structure variations through DNA and RNA sequencing
Authors:
- 19 April 2025
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 132 (12) , 1177-1187
Abstract
Background The detection of BRAF fusions by using next-generation sequencing (NGS) is essential for comprehensive analysis. Methods Data BRAF positive rearrangements from Chinese cancer patients were analyzed. DNA NGS was performed on FFPE samples, and RNA NGS was used to confirm fusion transcripts. Results BRAF fusions were identified in various cancers, predominantly glioma (87.8%). DNA NGS detected 371 BRAF fusion-positive samples, with 338 retaining the serine/threonine receptor tyrosine kinase domain (RTKD), divided into four groups: common (n = 254), rare (n = 66), intergenic (n = 7), and exonic (n = 11) fusions. Common fusions, mainly KIAA1549-BRAF, comprised the majority, with variations at introns 8, 9, and 10. Rare fusions and intergenic/exonic breakpoints displayed diverse structural patterns. RNA NGS verified transcriptional consistency in most samples from common fusions. However, various outcomes at the RNA level were found in other groups, involving mechanisms like alternative splicing, antisense rearrangement, and frameshift rearrangement. Additionally, 33 fusions lacked the RTKD, demonstrating significant structural diversity. Furthermore, 22 novel fusions were identified, which were distributed in tongue cancer, liver cancer, lung cancer, melanoma, brain cancer, and colon cancer. Conclusions Comprehensive molecular profiling and RNA sequencing are essential for accurate fusion detection, improving the design of NGS panels and aiding in the targeted therapy of BRAF fusion-positive cancers.Keywords
This publication has 30 references indexed in Scilit:
- Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancerLaboratory Investigation, 2018
- Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumorsNeuro-Oncology, 2015
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal CancerJournal of Clinical Oncology, 2015
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialThe Lancet Oncology, 2015
- The distribution of BRAF gene fusions in solid tumors and response to targeted therapyInternational Journal of Cancer, 2015
- A Novel Mechanism of EML4-ALK Rearrangement Mediated by Chromothripsis in a Patient-Derived Cell LineJournal of Thoracic Oncology, 2014
- Trimmomatic: a flexible trimmer for Illumina sequence dataBioinformatics, 2014
- Fusion genes and their discovery using high throughput sequencingCancer Letters, 2013
- BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade AstrocytomaClinical Cancer Research, 2011
- Human GC-AG alternative intron isoforms with weak donor sites show enhanced consensus at acceptor exon positionsNucleic Acids Research, 2001